Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection

被引：111

作者：

Fagan, SC

Edwards, DJ

Borlongan, CV

Xu, L

Arora, A

Feuerstein, G

Hess, DC

机构：

[1] Univ Georgia, Coll Pharm, Program Clin & Expt Therapeut, Augusta, GA USA

[2] Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA

[3] Vet Adm Med Ctr, Augusta, GA 30904 USA

[4] Wayne State Univ, Dept Pharm Practice, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI USA

[5] Merck & Co Inc, Dept Cardiovasc Res, Philadelphia, PA USA

来源：

EXPERIMENTAL NEUROLOGY | 2004年 / 186卷 / 02期

关键词：

minocycline; neuroprotection; dose; pharmacokinetics; blood-brain barrier; intraperitoneal;

D O I：

10.1016/j.expneurol.2003.12.006

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies. (C) 2004 Elsevier Inc. All rights reserved.

引用

收藏

页码：248 / 251

页数：4

相关论文

共 21 条

[1] Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury [J].

Arvin, KL ;

Han, BH ;

Du, YS ;

Lin, SZ ;

Paul, SM ;

Holtzman, DM .

ANNALS OF NEUROLOGY, 2002, 52 (01) :54-61

[2] Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease [J].

Chen, M ;

Ona, VO ;

Li, MW ;

Ferrante, RJ ;

Fink, KB ;

Zhu, S ;

Bian, J ;

Guo, L ;

Farrell, LA ;

Hersch, SM ;

Hobbs, W ;

Vonsattel, JP ;

Cha, JHJ ;

Friedlander, RM .

NATURE MEDICINE, 2000, 6 (07) :797-+

[3] Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat [J].

Colovic, M ;

Caccia, SB .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 791 (1-2) :337-343

[4] Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease [J].

Du, YS ;

Ma, ZZ ;

Lin, SZ ;

Dodel, RC ;

Gao, F ;

Bales, KR ;

Triarhou, LC ;

Chernet, E ;

Perry, KW ;

Nelson, DLG ;

Luecke, S ;

Phebus, LA ;

Bymaster, FP ;

Paul, SM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (25) :14669-14674

[5] Toward wisdom from failure - Lessons from neuroprotective stroke trials and new therapeutic directions [J].

Gladstone, DJ ;

Black, SE ;

Hakim, AM .

STROKE, 2002, 33 (08) :2123-2136

[6] Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum [J].

He, Y ;

Appel, S ;

Le, WD .

BRAIN RESEARCH, 2001, 909 (1-2) :187-193

[7] COMPARISON OF THE EFFECTIVENESS OF TETRACYCLINE AND MINOCYCLINE AS PLEURAL SCLEROSING AGENTS IN RABBITS [J].

LIGHT, RW ;

WANG, NS ;

SASSOON, CSH ;

GRUER, SE ;

VARGAS, FS .

CHEST, 1994, 106 (02) :577-582

[8] Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons [J].

Lin, SZ ;

Zhang, YQ ;

Dodel, R ;

Farlow, MR ;

Paul, SM ;

Du, YS .

NEUROSCIENCE LETTERS, 2001, 315 (1-2) :61-64

[9] Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction [J].

Mejia, ROS ;

Ona, VO ;

Li, MW ;

Friedlander, RM .

NEUROSURGERY, 2001, 48 (06) :1393-1399

[10] High-performance liquid chromatographic assay for minocycline in human plasma and parotid saliva [J].

Orti, V ;

Audran, M ;

Gibert, P ;

Bougard, G ;

Bressolle, F .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2000, 738 (02) :357-365